| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | GPRchr2; WI31133 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human GPR75 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于GPR75抗体的3篇文献概览(文献标题为虚构示例，仅供参考)：
1. **标题**：*"GPR75 Antibody Development for Metabolic Disorder Studies"*
**作者**：S. Wang et al.
**摘要**：研究团队开发了一种特异性靶向GPR75的单克隆抗体，验证其在体外和体内模型中抑制GPR75信号通路的能力，发现该抗体可通过阻断下游信号显著改善高脂饮食诱导的小鼠代谢紊乱。
2. **标题**：*"Therapeutic Targeting of GPR75 in Obesity via Neutralizing Antibodies"*
**作者**：L. Chen & R. Gupta
**摘要**：文章报道了一种中和抗体对GPR75的拮抗作用，证明其通过抑制GPR75与配体(如CCL5)结合，减少脂肪细胞分化和体重增加，提示其作为肥胖治疗药物的潜力。
3. **标题**：*"GPR75-Specific Antibodies Reveal Brain Expression Patterns in Neurodegeneration"*
**作者**：M. Rodriguez et al.
**摘要**：通过新型GPR75抗体的免疫组化分析，揭示了GPR75在小脑和海马体的高表达，并发现其在阿尔茨海默病模型小鼠中的表达异常，提示其与神经炎症的关联。
(注：以上文献为示例，实际研究中请通过PubMed或Google Scholar等平台检索真实文献。)
GPR75 (G protein-coupled receptor 75) is an orphan receptor belonging to the G protein-coupled receptor (GPCR) family, a class of membrane proteins involved in diverse physiological processes. Though its endogenous ligand remains unidentified, GPR75 has gained attention for its potential role in metabolic regulation and obesity. Studies suggest it may influence energy homeostasis by modulating hypothalamic signaling pathways related to appetite and weight control. For instance, *in vivo* models with GPR75 knockout exhibited resistance to diet-induced obesity, implicating the receptor in adiposity regulation.
GPR75 antibodies are essential tools for studying its expression, localization, and function. They enable detection of GPR75 in tissues like the brain, adipose tissue, and pancreas, aiding research into its tissue-specific roles. Additionally, these antibodies facilitate mechanistic studies, such as probing receptor activation, downstream signaling (e.g., cAMP or calcium pathways), and interactions with potential ligands or partners.
Therapeutic interest in GPR75 has surged due to its link to metabolic disorders. Neutralizing antibodies or antagonists targeting GPR75 are being explored for obesity treatment, aiming to mimic knockout phenotypes. However, challenges remain, including clarifying ligand-receptor dynamics and minimizing off-target effects. Overall, GPR75 antibodies bridge basic research and translational efforts, offering insights into metabolic disease mechanisms and therapeutic opportunities.
×
